Reaching Out to Improve Access to Radiation Therapy Treatment: Xstrahl attends regional conferences to meet with clinicians and discuss radiation therapy
Reaching Out to Improve Access to Radiation Therapy
read more
Products
Xstrahl to feature Radiant™ Aura at ASTRO 2023
Xstrahl, a global leader in the delivery of superficial radiation therapy devices and preclinical radiation research systems, will demonstrate Radiant Aura, a new low-dose, X-ray based, dual modality radiation therapy for treating non-melanoma skin cancers (NMSC) and keloid scarring at the American Society for Therapeutic Radiology and Oncology (ASTRO) Annual Meeting in San Diego, CA, October 1-3, 2023, booth #2216.
Antagonistic Effects of Ionising Radiation in Cell Competition
David Fernandez-Antoran PhD, Group Leader, The Gurdon Institute, University of Cambridge, Cambridge, UK ARAID Researcher, Head of Cell Competition and Radiation Biology Laboratory, IIS-Aragon, Zaragoza, Spain Ionising radiation is one of the most common environmental...
The Dermatology Insider 2023
The Dermatology Insider 2023 is Xstrahl’s magazine for dermatologists. This issue of the Dermatology Insider includes patient stories about having SRT treatment for their skin cancer. In addition, hear from a dermatologist as he describes his experience using radiation therapy to treat non-melanoma skin cancer (NMSC). See two case history reports of radiation therapy treatment for skin cancer using SRT and eBt, detailing the number of treatments, dose per treatment, reasons for radiation therapy, as well as before and after images of the results. Xstrahl introduces Radiant Aura, which recently received US Food & Drug Administration (FDA) 510(k) Clearance. We share more about using Radiant Aura and answer the most commonly asked questions in our FAQ section.
Xstrahl & SmART Scientific Solutions to showcase two new software solutions for radiation research at ICRR in Montréal, Canada
Xstrahl & SmART Scientific Solutions to showcase two new software solutions for radiation research at ICRR in Montréal, Canada
Xstrahl will demonstrate SmART-RAD and SmART-Contour at the 17th International Congress for Radiation Research (ICRR) August 27-30
Radiant™ Aura Receives U.S. Food and Drug Administration (FDA) 510(k) Clearance
Radiant™ Aura Receives U.S. Food and Drug Administration (FDA) 510(k) Clearance
Expands office-based treatment options for millions of non-melanoma skin cancer (NMSC) patients
Xstrahl, a global leader in the delivery of superficial radiation therapy devices and preclinical radiation research systems, announced its Radiant™ Aura treatment solution has received U.S. Food and Drug Administration (FDA) 510(k) clearance. With advanced features for expanded clinical use, simplified patient positioning, and additional patient comfort, Radiant Aura brings radiation therapy to NMSC patients in any dermatology office.
Using Radiation Therapy in the Veterinary Practice
Superficial and orthovoltage radiation therapy are used to treat many conditions with great results. See how Dr. Aurelia Klajer-Peres at Eiffelvet in France uses the Xstrahl system for both curative and palliative conditions.
Inorganic Scintillator Detectors for Dosimetry in Image-Guided Small Animal Radiotherapy Platforms
The purpose of the recent study, Characterization of Inorganic Scintillator Detectors for Dosimetry in Image-Guided Small Animal Radiotherapy Platforms, was to characterize a detection system based on inorganic scintillators and determine its suitability for dosimetry in preclinical radiation research.
kV Radiotherapy Treatment in Locally Advanced or Metastatic Breast Cancer
Researchers sought to understand the role of kV treatment in locally advanced and/or metastatic breast cancer in which kV radiotherapy was used as the primary modality or as supportive treatment to linac-based RT to gain local tumor control and improve the patient’s quality of life. See details of the recent study, Kilovoltage radiotherapy as a supportive treatment in locally advanced or metastatic breast cancer – a series of six case reports, and the full report on six cases.
Contact Us